Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bmab3000
- Development stage
- Phase 1
- Lead developer
- Viatris
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Bmab3000 is a biosimilar candidate for Herceptin Hylecta, a fixed-dose combination of trastuzumab and recombinant human hyaluronidase PH20. Trastuzumab is a humanized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), inhibiting tumor cell proliferation and mediating antibody-dependent cellular cytotoxicity (ADCC). The hyaluronidase component is an enzyme that temporarily depolymerizes hyaluronan in the subcutaneous extracellular matrix, increasing tissue permeability and allowing for the subcutaneous administration of large volumes of trastuzumab. Developed by Biocon Biologics in collaboration with Mylan (now Viatris), Bmab3000 is intended for the treatment of HER2-overexpressing breast cancer and gastric or gastroesophageal junction adenocarcinoma, providing a more convenient delivery alternative to intravenous formulations.
- Other names
- trastuzumab and hyaluronidase biosimilar
02
Targets
C1Q (Complement C1q)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)ERBB2 (Erb-b2 receptor tyrosine kinase 2)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on Bmab3000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bmab3000.